OLFADOG BIOTECH: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
OLFADOG BIOTECH
Largest movements
- Cash +€415,990
up €415,990 (+191%), from €217,536 to €633,526
mainly Contributions, distributions and other (+€786,640) and Depreciation (+€180,000)
- Intangible fixed assets -€120,000
down €120,000 (-11.1%), from €1.1m to €960,000
- Contributions +€786,640
up €786,640 (+63.0%), from €1.2m to €2.0m
- Trade debts -€310,169
down €310,169 (-46.3%), from €670,494 to €360,325
- Profit (loss) carried forward -€188,738
down €188,738 (-46.7%), from -€404,429 to -€593,166
- Depreciation -€184,505
down €184,505 (-50.6%), from €364,505 to €180,000
- Gross operating margin +€31,318
up €31,318 (+79.3%), from -€39,504 to -€8,187
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,515,065 | €1,802,799 | +€287,734 | +19.0% |
| Fixed assets | 21/28 | €1,080,000 | €960,000 | -€120,000 | -11.1% |
| Intangible fixed assets | 21 | €1,080,000 | €960,000 | -€120,000 | -11.1% |
| Current assets | 29/58 | €435,065 | €842,799 | +€407,734 | +93.7% |
| Amounts receivable within one year | 40/41 | €10,083 | €1,750 | -€8,332 | -82.6% |
| Other amounts receivable | 41 | €10,083 | €1,750 | -€8,332 | -82.6% |
| Cash at bank and in hand | 54/58 | €217,536 | €633,526 | +€415,990 | +191% |
| Deferred charges and accrued income | 490/1 | €207,446 | €207,522 | +€76 | 0.0% |
| Total equity and liabilities | 10/49 | €1,515,065 | €1,802,799 | +€287,734 | +19.0% |
| Equity | 10/15 | €844,571 | €1,442,474 | +€597,902 | +70.8% |
| Contributions | 10/11 | €1,249,000 | €2,035,640 | +€786,640 | +63.0% |
| Capital | 10 | €1,249,000 | €2,035,640 | +€786,640 | +63.0% |
| Issued capital | 100 | €1,249,000 | €2,035,640 | +€786,640 | +63.0% |
| Profit (loss) carried forward | 14 | -€404,429 | -€593,166 | -€188,738 | -46.7% |
| Amounts payable | 17/49 | €670,494 | €360,325 | -€310,169 | -46.3% |
| Amounts payable within one year | 42/48 | €670,494 | €360,325 | -€310,169 | -46.3% |
| Trade debts | 44 | €670,494 | €360,325 | -€310,169 | -46.3% |
| Suppliers | 440/4 | €670,494 | €360,325 | -€310,169 | -46.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €364,505 | €180,000 | -€184,505 | -50.6% |
| Other operating charges | 640/8 | €365 | €397 | +€32 | +8.7% |
| Gross operating margin | 9900 | -€39,504 | -€8,187 | +€31,318 | +79.3% |
| Operating profit (loss) | 9901 | -€404,375 | -€188,583 | +€215,791 | +53.4% |
| Financial charges | 65/66B | €54 | €155 | +€101 | +187% |
| Recurring financial charges | 65 | €54 | €155 | +€101 | +187% |
| Profit (loss) for the period before taxes | 9903 | -€404,429 | -€188,738 | +€215,691 | +53.3% |
| Profit (loss) for the period | 9904 | -€404,429 | -€188,738 | +€215,691 | +53.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€404,429 | -€188,738 | +€215,691 | +53.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 14 October 2026 via checked.be.